HAG
MRNA icon

HighPoint Advisor Group’s Moderna MRNA Stock Holding History

HighPoint Advisor Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,223
Closed -$502K – 719
2024
Q2 		$502K Buy
4,223
+769
+22% +$97.3K 0.03% 350
2024
Q1 		$434K Sell
3,454
-990
-22% -$99.8K 0.03% 385
2023
Q4 		$491K Buy
+4,444
New +$374K 0.04% 357
2022
Q2 		$241K Buy
+1,509
New +$216K 0.03% 450
2021
Q3 		$1.69M Buy
4,377
+2,898
+196% +$1.07M 0.17% 114
2021
Q2 		$348K Buy
+1,479
New +$264K 0.04% 370
2021
Q1 		– Sell
-1,322
Closed -$237K – 532
2020
Q4 		$237K Sell
1,322
-13,226
-91% -$1.34M 0.03% 399
2020
Q3 		$1.04M Buy
14,548
+2,662
+22% +$186K 0.19% 104
2020
Q2 		$732K Buy
+11,886
New +$651K 0.16% 120

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HighPoint Advisor Group's MRNA Position: Q3 2024 in Review

HighPoint Advisor Group sold out of Moderna (MRNA) in Q3 2024, closing a stake of 4,223 shares — an estimated $502K sold.

HighPoint Advisor Group first reported a position in MRNA in Q2 2020 and held it in 9 quarters. The position peaked at $1.69M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • HighPoint Advisor Group reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • HighPoint Advisor Group sold 4,223 Moderna shares in Q3 2024, an estimated $502K.
  • HighPoint Advisor Group first reported a position in Moderna in Q2 2020 and held it in 9 quarters.
  • HighPoint Advisor Group's Moderna position peaked at $1.69M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on HighPoint Advisor Group's 13F filing for Q3 2024, filed 4 Nov 2024.